New drug cocktail shows promise in battling bone marrow cancer
NCT ID NCT04822337
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new drug called belantamab mafodotin when added to three standard chemotherapy drugs (carfilzomib, lenalidomide, and dexamethasone) for people with multiple myeloma, a type of blood cancer. The goal is to find the safest dose and see if this combination can improve how well the cancer responds. About 70 participants will be enrolled in this early-phase trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin, carfilzomib, lenalidomide, dexamethasone
What this could lead to
If successful, this combination could offer a more effective treatment option for multiple myeloma, potentially leading to better disease control.
What could go wrong
This is an early-phase trial with a small number of participants. The combination may cause significant side effects, and it is not yet known if it will be better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States